Navigation Links
InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
Date:9/12/2011

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to the commercial launch for Esbriet® (pirfenidone) in Germany and other countries in the EU, and statements regarding timing of the ASCEND trial enrollment.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) risks related to our ability to successfully launch and commercialize Esbriet in the EU, including successfully establishing a commercial operation in the EU and receiving favorable governmental pricing and reimbursement approvals in each EU country; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
2. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
3. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune Reports Third Quarter 2010 Financial Results
6. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
7. InterMune to Release Second Quarter Financial Results on July 27
8. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
9. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
10. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
11. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Texas , March 5, 2015 ... bio-analytical solutions company focused on gynecologic disease, announced ... financial results before the market open on Wednesday, ... call and webcast at 8:30am Eastern. Conference Call ... 2015 at 8:30am Eastern/5:30am Pacific Domestic: , 800-753-9057International: ...
(Date:3/5/2015)... March 5, 2015  BioPhotas, Inc., an FDA registered ... patented photo-therapeutic technologies to treat skin, muscle and joint ... Semper Fi Fund to provide BioPhotas, flagship product, the ... pain management solutions.  Commenting on the ... who used the Celluma at the Warrior Hope and ...
(Date:3/5/2015)... 5, 2015  Medical Diagnostic Laboratories, L.L.C., (MDL), ... complexity, state-of-the-art, automated DNA-based molecular analyses, announces that ... testing which utilizes cutting edge technology, including next- ... approximately 12,000 women are diagnosed with cervical cancer ... Genital Human Papillomaviruses (HPV) are a group of ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... 27 Pharmacopeia,(Nasdaq: PCOP ), an ... novel,small molecule therapeutics, announced today that the ... Program for Research and Training,in Tropical Diseases ... antimalarial,agents. Pharmacopeia will receive funding to conduct ...
... Mass., Aug. 23 Biopure Corporation,(Nasdaq: BPUR ) ... ended July 31, 2007. For the quarter, the company ... common share, compared with a net loss,of $6.6 million, ... in,2006. Class A common shares outstanding on July 31, ...
Cached Medicine Technology:Biopure Announces 2007 Third Quarter Financial Results 2Biopure Announces 2007 Third Quarter Financial Results 3Biopure Announces 2007 Third Quarter Financial Results 4Biopure Announces 2007 Third Quarter Financial Results 5Biopure Announces 2007 Third Quarter Financial Results 6Biopure Announces 2007 Third Quarter Financial Results 7
(Date:3/5/2015)... 2015 A Bakersfield, Calif. state court jury ... trial awarding the plaintiff Coleen M. Perry a total of ... a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., ... , a partner at Wagstaff & Cartmell in ... plaintiff, along with Rich Freese and Tim Goss of ...
(Date:3/5/2015)... Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) filed ... strokes and other serious cardiovascular events due to their ... forward in the federal multidistrict litigation now underway in ... a Case Management Order issued on March 3rd, the ... master pleadings in the proceeding. Among other things, the ...
(Date:3/5/2015)... HomeCEUConnection.com is proud to support Nutrition ... their nutrition CEUs. To raise awareness on ... is offering 10% off selected nutrition CEU ... . , High Quality Continuing Education for ... continuing education courses for Physical Therapists, Physical ...
(Date:3/5/2015)... 05, 2015 SuperCloset has released a new ... series aims to teach viewers everything they need to know ... Like a SuperPro takes you from seed all the way ... clone, to how to prune Grow Like a SuperPro will ... the whole series for download for a special introductory price ...
(Date:3/5/2015)... March 05, 2015 At the ... Beyond,” leaders in addiction treatment met today in Jackson, ... best clinical practices. Among the numerous respected speakers will ... will address the role that pain medications have had ... evidence-based treatment options. , "It is hard to believe ...
Breaking Medicine News(10 mins):Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... July 10 Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider of ... 21 to discuss the,company,s second quarter 2008 financial results., What: ... When: July 21, 2008, 1:30 p.m. PDT ... Rob Seim, ...
... the cancer in young men haven,t changed, study says , , ... deadliest form of skin cancer, are increasing sharply among younger ... a new study says. , "These findings are important, ... about the risks of skin cancer from sun tanning do ...
... Nutritional Wonder Hair Growth Creme & Acne Treatment Kit, ... a,staggering four million in the US alone, and the realization ... Herbalist and,Cosmetologist, Chatto Wright, has created Chatto 6 Plus Growth ... treatment which offers a solution to,the ever-increasing statistics of hair ...
... Tool Aims to Improve Genetic Healthcare and ... July 10 DNA Direct, Inc. and,Iverson ... companies will,collaborate to offer personalized reports for ... to warfarin, a,commonly used anticoagulant. DNA Direct ...
... Now Requires Screening for 28 Genetic, Metabolic Conditions, ... month by Governor Edward G. Rendell will help to ... state Health Department., By amending the Newborn Child ... of Health to continue to provide for screening and ...
... Reports Economic Activity Twice as Large as Reported Last ... ... A collaborative of Massachusetts,leading human services associations today lauded a study conducted ... state,s human services industry could be as high as,$437 million, twice as ...
Cached Medicine News:Health News:Omnicell to Release Second Quarter 2008 Earnings Results on July 21 2Health News:Melanoma Rates Soar Among Younger Women 2Health News:Melanoma Rates Soar Among Younger Women 3Health News:Video: Chatto Skincare Unprecedented Breakthrough 2Health News:Video: Chatto Skincare Unprecedented Breakthrough 3Health News:DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results 2Health News:DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results 3Health News:New Law Signed by Governor Rendell Expands Newborn Screening in Pennsylvania 2Health News:New Study Shows Human Services Impact May Be $430 Million 2
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
...
Design of the Global Advantage Shoulder for shoulder replacement surgery is based on detailed studies of the shoulder, its structure and how it works....
Medicine Products: